

Visit by the Deputy Minister of International Trade and Industry (MITI) and The Deputy Chief Executive Officer II of MIDA to Novugen Pharma and Novugen Oncology (formerly known as Oncogen Pharma)

BANDAR BARU ENSTEK, NEGERI SEMBILAN, 18 March 2021 – The Deputy Minister of International Trade and Industry (MITI), YB Senator Datuk Lim Ban Hong, accompanied by the Deputy Chief Executive Officer II of the Malaysian Investment Development Authority (MIDA), Mr. Ahmad Khairuddin Abdul Rahim, visited the Research and Development (R&D) centre and manufacturing plants of Novugen Pharma (Malaysia) Sdn Bhd and Novugen Oncology Sdn Bhd (formerly known as Oncogen Pharma) earlier today at Bandar Baru Enstek, Negeri Sembilan.

Received by the Chief Executive Officer of Novugen Pharma and Novugen Oncology, Mr. Rahil Mahmood and the Executive Committee Members of Novugen Pharma and Novugen Oncology, the entourage was briefed on the companies' business operations and research activities.

Established in 2015, Novugen Pharma and Novugen Oncology strive to establish Malaysia's first vertically integrated pharmaceutical business of global standards in Malaysia. The plants, equipped with state-of-the-art facilities are also the only fully integrated and fully automated facilities in ASEAN offering high quality affordable medicines for cancer patients, apart from catering to other critical therapeutic areas.

YB Senator Datuk Lim Ban Hong applauded the companies' achievement, "We are proud that Novugen had recognised Malaysia as an ideal location to establish their first vertical integration pharmaceutical facility and as a global hub. We believe that Novugen will benefit from the established quality infrastructure and a pool of young talented scientists in Malaysia. The presence of Novugen will contribute to raising the standard of our pharmaceutical industry and lift Malaysia as a nucleus for global pharmaceutical manufacturing."

Mr. Rahil Mahmood thanked YB Senator Datuk Lim Ban Hong and Mr. Ahmad Khairuddin for taking the time to visit the R&D facility and the manufacturing plants. "We were delighted to welcome the Deputy Minister and Deputy CEO II of MIDA for the first visit and their presence today signifies the strong contribution of Novugen Pharma and Novugen Oncology to Malaysia's and the global health sector and economy."



"We have invested more than RM508 million in Malaysia till date to build state-of-the-art R&D and manufacturing facilities. With these facilities, Novugen Oncology Pharma and Novugen Pharma will be able to develop, manufacture, sell and distribute pharmaceutical drug products for exporting to more than 75 countries as well as for domestic market. We will also create more than 2,000 professional and skilled jobs in Malaysia by 2030."

"We would like to commend both MITI and MIDA for their unwavering support to ensure the success of Novugen Pharma and Novugen Oncology in the country, as we continue to spearhead our efforts and work closely with all relevant ministries to bring Malaysia's pharmaceutical industry to a higher level", concluded Rahil.



Group photo of YB Senator Datuk Lim Ban Hong (front row -3rd from right), Encik Ahmad Khairuddin (front row - 2nd from right), Mr Rahil Mahmood (front row 3rd from left).



Group photo of the delegations in front of the Oncogen Pharma R&D and Manufacturing Plant.



YB Senator Datuk Lim Ban Hong (right) was briefed on the Delegations during the tour of the Plant. Oncogen Pharma R&D and Manufacturing Plant.



nevugen





Delegations during the tour of the Plant.

About Novugen Pharma (Malaysia) Sdn Bhd

Novugen Pharma (Malaysia) Sdn. Bhd. is a wholly owned subsidiary company of a UAE based group with more than 25 years of experience in strategic healthcare businesses and development of world class healthcare facilities around the globe. Novugen's globally minded strategy, synergistic approach and wealth of experience enable us to respond to the complex challenge of bringing hard-to-source and technology-intensive products to market while maintaining affordable pricing and rigorous quality assurance. As a technology leader, we create efficiency by integrating our total value chain. At Novugen, our science and business teams work together seamlessly to innovate new concepts and fresh ideas to accelerate the launch of pharmaceuticals that lack robust generic alternatives due to their complexity.

Website: www.novugen.com

About Oncogen Pharma (Malaysia) Sdn Bhd

Oncogen Pharma (Malaysia) Sdn Bhd is a fully integrated research based pharmaceutical company with a global outlook to cancer treatment. Based in Malaysia, it is one of the fastest growing Pharmaceutical company in the country with the largest portfolio of Oncology products under development. Oncogen Pharma has established the most advanced R&D facilities for developing Oncology APIs and formulations for regulated markets. The diversified and qualified technical team of top professionals from different parts of the world have deep experience & exposure of the development of strategic products for global markets.

Oncogen's API and Formulation plants are set-up close to each other on over 8 acres of land in Enstek Park, Malaysia and are designed by international experts following stringent regulatory requirements by authorities across the globe including USFDA, EMA, PIC/S and WHO.

Website: www.oncogenpharma.com

